Recruiting Neuropathy Studies in Maitland
A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)
The purpose of this Phase 3 study is to demonstrate the efficacy of DNTH103 as compared to placebo in participants with chronic inflammatory demyelinating polyneuropathy (CIDP)....
IMVT-1402 in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
This is a Phase 2b study to evaluate the efficacy and safety of IMVT-1402 in adults with CIDP....
About Neuropathy Clinical Trials in Maitland
Neuropathy refers to damage or dysfunction of peripheral nerves, causing weakness, numbness, and pain, typically in the hands and feet. Diabetes is the most common cause, but it can also result from infections, injuries, and autoimmune conditions. Treatment focuses on managing the underlying cause and pain relief.
There are currently 2 neuropathy clinical trials recruiting participants in Maitland, FLORIDA. These studies are seeking a combined 642 participants. Research is being sponsored by Dianthus Therapeutics, Immunovant Sciences GmbH. Clinical trial participation is free and participants receive study-related medical care at no cost.
Neuropathy Clinical Trials in Maitland — FAQ
Are there neuropathy clinical trials in Maitland?
Yes, there are 2 neuropathy clinical trials currently recruiting in Maitland, FLORIDA. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Maitland?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Maitland research site will contact you about next steps.
Are clinical trials in Maitland free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Maitland studies also compensate for your time and travel.
What neuropathy treatments are being tested?
The 2 active trials in Maitland are testing new therapies including novel drugs, biologics, and treatment approaches for neuropathy.
Data updated March 2, 2026 from ClinicalTrials.gov